In a recent interview with Investment Reports, our CEO Thierry BERNARD discusses why molecular testing has never been more crucial than it is today. And why he sees QIAGEN better positioned than ever to address the industry's shifting trends, including the emergence of generative AI. Learn more 👉 https://lnkd.in/eR2tH6G2
QIAGEN
Biotechnology Research
Venlo, Limburg 261,727 followers
Making improvements in life possible
About us
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
- Website
-
http://www.qiagen.com
External link for QIAGEN
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Venlo, Limburg
- Type
- Public Company
- Specialties
- Life science research, Molecular diagnostics, Applied testing (forensics, food safety testing, veterinary medicine), Pharmaceutical research, and bioinformatics
Locations
Employees at QIAGEN
Updates
-
It’s official: Our clinical decision support platform QIAGEN Clinical Insight Interpret is now IVDR certified in Europe. Learn more 👉 https://lnkd.in/eDSETCVJ ✅ The updated version of QIAGEN Clinical Insight Interpret is the first NGS interpretation platform approved for diagnostic use in both oncology and hereditary applications. ✅ As medical device software for clinical decision support, it conforms with regulatory policy, ensuring greater patient protection, information transparency, and data traceability. ✅ With over 4 million NGS patient test cases for oncology and hereditary diseases processed worldwide, QIAGEN Clinical Insight Interpret supports confident decision-making in genetic testing.
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
corporate.qiagen.com
-
🎉 Exciting news: The FDA has cleared our QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. Learn more 👉 https://lnkd.in/ehvJRxiU ✅ Our panel is designed to support fast clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets. ✅ With results available in about one hour and requiring less than one minute of hands-on time, QIAstat-Dx provides direct access to critical diagnostic details, including Ct values and amplification curves, ensuring deeper insights into patient results. ✅ By improving the detection of co-infections and enabling faster, informed clinical decisions, our QIAstat-Dx panel reduces the need for unnecessary antibiotics, contributing to global efforts in antimicrobial stewardship.
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
corporate.qiagen.com
-
In collaboration with the Federal Bureau of Investigation (FBI), we are set to boost forensics by developing a digital PCR assay for our QIAcuity systems that improves DNA quantification in human samples. Read more 👉 https://lnkd.in/g5yaYgVc ✅ Our collaboration aims to develop a first-of-its-kind dPCR assay that can quantify in absolute terms nuclear and mitochondrial DNA concentrations, male DNA, and include quality markers for degradation and inhibition. ✅ Compared to traditional quantitative PCR, dPCR boasts a higher tolerance to inhibitors, enabling forensic specialists to detect and quantify even minimal amounts of DNA. This capability significantly improves the success rate of forensic analysis while saving time and money. ✅ Better DNA quantification will allow the forensic community to more quickly, accurately, and reliably analyze a broader range of evidence, even from challenging samples. This advance in forensic science proves the relevance of dPCR in enhancing the reliability and impact of forensic evidence in convicting the guilty and exonerating the innocent.
QIAGEN partners with the FBI to develop digital PCR assay for QIAcuity for use in forensics
corporate.qiagen.com
-
Hey, #ClinicalLabs, we know you feel it—the burdensome complexity and time-consuming traditional #PCR workflows that involve multiple machines and specialized personnel to run. Here’s news that’ll help lighten the load. Now you can do it all with just one machine. Introducing #QIAcuityDx, our single touchpoint, benchtop dPCR system that’ll save your lab time, space and get you results fast. There’s no better time than now to update and refresh your PCR workflow. Learn more 👉 https://lnkd.in/eyqwwj_G
This content isn’t available here
Access this content and more in the LinkedIn app
-
We are thrilled to announce the launch of our cloud-based software QCI Secondary Analysis that enhances bioinformatics workflows for oncology and inherited disease applications. Learn more 👉 https://lnkd.in/eQ3_h56g ✅ QCI Secondary Analysis is validated for use for all QIAseq NGS panels and directly integrated with QCI Interpret, our clinical variant interpretation and reporting software, and enables high-throughput secondary analysis of clinical NGS data. ✅ With QCI Secondary Analysis, we want to empower molecular testing labs, regardless of size, budget, and experience, to leverage the power of comprehensive genomic information to advance precision medicine in every setting. ✅ QCI Secondary Analysis is designed to streamline analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
corporate.qiagen.com
-
Say goodbye to complicated #digitalPCR workflows, and hello to simplicity. Learn more 👉 https://lnkd.in/eqARQDnQ Here’s why your lab will love #QIAcuityDx: ✅ It’s got a quick, simple and easy-to-run qPCR-like workflow. ✅ It minimizes hands-on time so your lab operator gets time back for other tasks. ✅ You can simultaneously run multiple plates with different settings, and continually remove and load new plates – so busy labs like yours can quickly adapt to changing needs. ✅ If you’re running your own assays, it offers a simplified route to develop and run your own assay menu using a quality IVD instrument.
-
We exceeded our outlook for Q1 2024 and are on track to achieve our full-year 2024 guidance. Read more 👉 https://lnkd.in/gcU6bTer ◾ Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46. ➡ Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook. ➡ Excluding COVID-19 product groups, net sales decline 1% CER. ➡ Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx. ➡ 25.7% adjusted operating income margin on efficiency gains vs. 25.6% in Q1 2023. ➡ Strong operating cash flow rises 85% to $133 million vs. Q1 2023. ◾ 2024 outlook reaffirmed for at least $2.0 billion CER net sales and adj. diluted EPS of at least $2.10 CER.
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
corporate.qiagen.com
-
🎉 Exciting news: We expand our tuberculosis portfolio with the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for advanced TB research and surveillance. Learn more: https://lnkd.in/gYpJsnXH ✅ A leap forward in TB control, our new panel allows for culture-free WGS, speeding up TB outbreak tracking and detection of antimicrobial resistance. ✅ The panel simplifies the identification of TB strains and their resistance profiles, aiding in faster and more accurate public health responses. 📍 Discover the QIAseq xHYB Mycobacterium tuberculosis Panel and experience our range of diagnostic solutions firsthand at ESCMID 2024. Meet us at booth D20!
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
corporate.qiagen.com
-
🧬 Happy DNA Day! Did you know that when DNA was first discovered, it wasn't called DNA at all? In 1869, Friedrich Miescher isolated a mysterious phosphorous-rich acidic substance from the nuclei of white blood cells during his experiments at the University of Tuebingen. This substance, reflecting its origin and properties, was given a particular name by Miescher.
This content isn’t available here
Access this content and more in the LinkedIn app
Affiliated pages
Similar pages
Browse jobs
Stock
QGEN
NYSE
20 minutes delay
$45.69
-0.3 (-0.652%)
- Open
- 45.81
- Low
- 45.62
- High
- 45.915
Data from Refinitiv
See more info on